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Abstract Here we describe a novel purinergic receptor, the 
P2X5 receptor, cloned from rat heart. The full-length cDNA 
encodes a protein 455 amino acids long which shares an overall 
identity of 40-47% with other members of the P2X purinergic 
receptor family. P2X5 mRNA transcripts are found predomi- 
nantly in rat heart but are also present in brain, spinal cord and 
adrenal gland. Functional expression of the recombinant receptor 
in HEK-293 cells shows a current that resembles mostly the 
P2X2 phenotype: the ATP-activated current reveals little 
agonist desensitization, is not activated by a,~meATP and is 
completely blocked by suramin and PPADS. 
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1. Introduction 
The physiological actions of extracellular ATP have been 
comprehensively described and include contractile regulation 
of cardiac, vascular and visceral smooth muscle, excitatory 
and inhibitory effects on neurons from the central and per- 
ipheral nervous ystem and activation of neuroendocrine s - 
cretion (for reviews ee [1-3]). All these effects are apparently 
mediated by a miscellaneous group of G-protein coupled re- 
ceptors (P2Y) and ligand-gated channels (P2X) [4]. To date, 
despite the numerous functions attributed to extracellular 
ATP, only four P2X receptors have been identified: P2X1 
[5], P2X2 [6], P2X3 [7,8] and P2X4 [9-13]. Analysis of the 
amino acid sequences provides evidence of a novel family of 
membrane proteins consisting of two short intracellular do- 
mains, two transmembrane-spanning motifs, and a large ex- 
tracellular loop comprising 10 conserved cysteines. These re- 
ceptors are structurally unrelated to other ligand-gated 
channels [14]. 
Analysis of P2X mRNA expression reveals a broad distri- 
bution of P2X1, P2X2 and P2X4 transcripts throughout the 
major tissues of the body [5,6,9,12,13,15], indicating a role of 
these proteins in many different physiological ctions. In con- 
trast, P2X3 transcripts have a localization limited to nocicep- 
tive neurons corresponding to C-fibre afferents of dorsal root 
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Abbreviations: a,13-meATP, a,13-methylene-ATP; 13,y-meATP, 13,7- 
methylene-ATP; PPADS, pyridoxal phosphate 6-azophenyl-2',4'- 
disulphonic acid; TEA-C1, tetraethylammonium chloride; 2MeSATP, 
2-methylthio-ATP; ECs0, half-maximal effective concentration; a, 
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ganglia [8]. In addition to expressing P2X3 receptors, these 
neurons also hold transcripts of all P2X1 to 4 isoforms. In- 
deed, P2X2/P2X3 heteromultimeric eceptors have been pro- 
posed to occur in vivo [7]. This raises the fascinating possibi- 
lity that ATP is involved in the generation of pain signals 
[7,8,16]. 
Heterologous expression of each recombinant P2X isoform 
results in ATP-activated cation-selective channels with diverse 
pharmacological nd desensitization phenotypes [5-13,17]. 
The main pharmacological distinction is their the relative sen- 
sitivities to the agonist a,13-meATP and the antagonists sur- 
amin and PPADS. Thus, a,13-meATP is a full agonist for 
P2X1 and P2X3 receptors [5,7,8,17], but is not effective on 
the P2X2 and P2X4 forms [9-13,17]. On the other hand, P2X4 
is the only purinergic receptor cloned so far that is insensitive 
to the established P2X blockers suramin and PPADS 
[9,10,12,13]. 
The weak reciprocity between the phenotypes reported for 
heterologous expressed recombinant P2X receptors and the 
responses observed in native systems indicates that additional 
subunits might occur. In this paper we describe the cloning 
and functional expression of a new rat receptor, P2X5, be- 
longing to the P2X ATP-gated channel family. 
2. Materials and methods 
2.1. Isolation of the P2X5 cDNA 
A partial cDNA sequence for the P2X5 receptor (~400 bp) was 
obtained from rat heart cDNA by degenerate PCR. The PCR thermal 
profile was: 5 min at 94°C/5 cycles of 1 min at 94°C, 45°C followed by 
30 cycles of 1 min at 94, 50 and 72°C. The forward primer was: 5'- 
TG(G/T)CIG(C/G)ITGGTGCCC(G/T)GT(G/A)GAG-3'; the reverse 
primer was: 5'-TAC(C/T)TGGCAAA(T/C)CTGAA(A/G)TTG(A/ 
T)AGC-3'. To isolate the unknown 5' and 3' sequences we used the 
Marathon cDNA amplification kit (Clontech) based on a modification 
of the ligation-anchored PCR amplification technique [18]. Specific 
oligonucleotides targeted to the P2X5 sequence were extended by 
nested PCR (Expand Long Template PCR system, Boehringer-Mann- 
heim) towards the 5' and 3' mRNA ends, using a library of adaptor- 
ligated cDNA (constructed from rat brain polyA + mRNA) and fol- 
lowing the manufacturer's recommendations. Finally, to obtain a full- 
length P2X5 coding sequence, specific oligonucleotides were used to 
amplify by PCR a rat heart cDNA. To avoid Taq DNA polymerase 
random mutations, DNA fragments from independent PCR reactions 
were isolated and cloned. Sequences from both strands were deter- 
mined. 
2.2. Transient transfection fHEK 293 cells 
The full-length P2X5 cDNA was subcloned into the mammalian 
expression vector pcDNA3 (Invitrogen). Human embryonic kidney 
cells (HEK-293 cells, ATCC CRL 1573) were transfected (200-500 
ng/dish) using a modified calcium phosphate precipitation technique 
[19]. Transfected cells were incubated for ~40 h before lectrophy- 
siological experiments. 
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2.3. Electrophysiological recordings 
Transfected cells were continuously perfused at room temperature 
with an extracellular bath solution containing (mM): 150 NaC1, 
2 CaC12, 1 MgC12, 2 KC1, 10 HEPES, 12 glucose (pH 7.3). Patch 
pipettes were made from borosilicate glass and filled with an intracel- 
lular solution containing (mM): 120 CsCl, 20 TEA-C1, 1 CaC12, l 
MgCI2, 11 EGTA, 10 HEPES (pH 7.2). Membrane currents were 
recorded from cells using an EPC-9 amplifier (HEKA Electronik, 
Lambrecht). Whole-cell currents were sampled at 20 Hz and stored 
on disk. The membrane potential was clamped at -70  mV in all 
experiments. Pipette resistance was 6-8 Mf~ and the series resistance 
was compensated by up to 70%. Agonist and antagonist were applied 
in bath solution with a microcapillary application system. Wild-type 
HEK-293 cells did not show significant endogenous ATP responses 
within the range of concentrations used. To ensure complete recovery 
from desensitization between sucesive agonist applications, we used 
wash periods of 1 min. Dose-response curves of ATP-activated whole- 
cell currents were fitted with the sigmoidal function 
l=Im~/(1 +(EC~0/C)~"), where Im~ is the maximal current, C 
the agonist concentration, ECs0 the half-maximal efective concentra- 
tion and nH the Hill coefficient. Results are expressed as mean + S.D. 
2.4. P2X5 mRNA tissue distribution analysis by RT-PCR 
Total RNA was prepared from freshly dissociated tissues by the 
single-step method [20]. First strand cDNA syntheses (Superscript II 
reverse transcriptase, GibcoBRL) were independently primed with 
oligo(dT) and random hexamers (5 Ixg total RNA, in 20 ~tl reaction 
volume). The PCR reactions were performed in 50 HI final volumes 
containing 1 ~1 of cDNA, 0.5 ~tM each of pairs of P2X5 and trans- 
ferrin receptor (TFR)-specific primers (ref), 200 pM dNTPs, 2.5 units 
Taq DNA polymerase, and 1 × Taq DNA polymerase reaction buffer 
(Promega). The PCR thermal profile was 5 min at 94°C and 35 cycles 
of 40-60 s at 94, 59 and 72°C. The P2X5 primers were 5'- 
CGCTGGGGAGTCTGTTGTAG-3' (forward, F1) and 5'- 
TCTCGGTAAAACTCACTC-3' (reverse, R1). The PCR fragment 
length was 698 bp. Southern blot analysis of PCR products was per- 
formed at high stringency with appropriate c~-[32p]dCTP random- 
primed probes for the TFR and P2X5 genes. An identical result 
was obtained using the same PCR conditions and an antisense primer 
to the 3' untranslated region of the P2X5 gene: 5'-TGGAGTT- 
GAGGGGCTTTTCT-3' (reverse, R2). The PCR fragment size was 
1083 bp. 
To rule out the possibility of genomic DNA contamination of the 
cDNAs, we performed PCR control reactions under the same condi- 
tions but using 0.5 Ixg of rat genomic DNA. No bands were detected 
(Fig. 2B), suggesting that the P2X5 oligonucleotides flank intronic 
structures. The integrity of the genomic DNA control was assessed 
(data not shown) by amplification with specific primers for the Kvl.4 
potassium channel (a gene with no introns). 
2.5. Drugs 
ATP (disodium salt), CTP (sodium salt), UTP (sodium salt), c~,13- 
MeATP (lithium salt), [3,y-MeATP (sodium salt), dATP (sodium salt) 
and AMP (sodium salt) were obtained from Sigma; GTP (disodium 
salt) was purchased from Fluka; ADP (free acid) was obtained from 
Boehringer Mannheim; PPADS (tetrasodium salt) and 2MeSATP 
(tetrasodium salt) were obtained from Research Biochemicals Inc.; 
suramin was purchased from Calbiochem. 
3. Results and discussion 
3.1. Cloning of the P2X5 receptor 
Using PCR techniques we have isolated a new eDNA from 
rat heart. The deduced amino acid sequence revealed a new 
protein with high structural homology to the previously de- 
scribed P2X receptors. Fol lowing the accepted nomenclature 
and classification of  purinoceptors we designate this protein as 
P2X5. The new eDNA encodes a 455 amino acid protein (Fig. 
1) that contains the structural patterns previously described 
for the P2X receptor family [14]. Two hydrophobic amino 
acid stretches could constitute a pair of  transmembrane seg- 
ments, connecting a large extracellular loop (comprising 10 
cysteine residues) to the cytosolic N-  and C-terminal seg- 
ments. The amino acid identity of  the P2X5 protein with 
the other members of  the P2X family is: P2X1 (41%), P2X2 
(45%), P2X3 (43%) and P2X4 (47%). Like all the cloned P2X 
receptors, the P2X5 isoform exhibits maximum amino acid 
homology within the central core of  the protein (bracketed 
by the two putative transmembrane segments) but any kind 
of  resemblance is lost at the C-terminal segment (Fig. 1). The 
P2X5 receptor contains three N-glycosylat ion consensus sites, 
N-X-(ST),  located in the putative extracellular loop but none 
of  them is conserved throughout all the members of  the P2X 
family. Additionally, the new P2X isoform holds four protein 
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Fig. 1. Aligment of deduced amino acid sequences for the cloned rat P2X receptors. Residues conserved in all five sequences are denoted by 
open boxes. The two presumed transmembrane-spanning segments are underlined, the putative sites for P2X5 N-linked glycosylation are indi- 
cated by an open circle, and the protein kinase C consensus equences by a closed circle. The sequence for the P2X5 eDNA has been submitted 
to the EMBL Nucleotide Sequence Database with the following accession umber: X97328. 
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Fig. 2. (A) Analysis of P2X5 mRNA tissue expression by RT-PCR (oligonucleotides S1, R1) and Southern blot autoradiography using a 
P2X5-specific probe (P2X5 arrow) and a rat transferrin receptor probe (TFR arrow). H20: control samples without cDNA. (B) Ethidium bro- 
mide stained agarose gel of RT-PCR products (5 I.tl, oligonucleotides S1, R2) for brain, spinal cord, adrenal gland and heart. The PCR prod- 
ucts from a genomic DNA amplification (0.5 ~tg) are shown. Note that no relevant fragments were amplified, indicating that the P2X5 oligonu- 
cleotides did specifically amplify the cDNA. Southern blot analysis of the genomic DNA sample revealed no hybridization signals (data not 
shown). We obtained an equivalent result using the oligonucleotides S1 and R1. H20: control sample without cDNA. 
kinase C (PKC) consensus sites, (ST)-X-(KR), but only two of 
them are positioned in the N-terminal domain, presumably 
facing the cytosol. Interestingly, one of these PKC sites is 
conserved throughout all the P2X isoforms (Fig. 1). 
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Fig. 3. (A) Inward currents evoked by ATP, 2MeSATP and ADP in HEK-293 cells transfected with P2X5 cDNA (B) Current-voltage r lation- 
ship obtained through voltage ramps. (C) Dose-response curves for ATP (open triangles) and 2MeSATP (inverted open triangle). Responses to 
ADP (open diamond) and ctl3-meATP (open circle) are indicated. 
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Table 1 
P2X5 responses and ECs0 achieved upon the application of various compounds 
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Compound laM/ECs0 (/.tM) % response nH N 
ATP 500/EC50 = 8 + 2 100 1.3 + 2 
2MeS ATP 500/EC50 = 15 + 4 105 + 5 1.4 + 2 
cxl3-meATP 500 < 3 
13,T-meATP 500 9 + 5 
ADP 500 29 + 10 
AMP 500 41 + 14 
Adenosine 500 < 5 
dATP 500 13 + 4 
CTP 500 < 2 
GTP 500 < 6 
UTP 500 < 3 
The currents are expressed as the percentage (mean + S.D.) of the maximal response obtained with 500 ~tM ATP. 
3.2. Tissue distribution of  P2X5 mRNA expression 
Tissue distribution of P2X5 transcripts was assessed by RT- 
PCR and the resulting PCR products (oligonucleotides S1, 
R1) were analyzed by Southern blotting (Fig. 2A). This P2X 
isoform showed a more restricted mRNA expression pattern 
than those observed for P2X1, P2X2 and P2X4 receptors 
[5,6,9,12,13]. Transcripts were detected only in a few major 
tissues, namely brain, heart, spinal cord and adrenal gland. To 
guarantee the specificity of the RT-PCR assay, we repeated 
the PCR reactions using an antisense oligonucleotide targeted 
to the P2X5 3' untranslated region (oligonucleotide R2), and 
obtained an identical result. Although we did not attempt 
quantitative analysis of P2X5 transcript expression levels, a 
visual estimation of the PCR product yield (stained with ethi- 
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Fig. 4. (A) Effects of suramin when co-applied with 10 /.tM ATP. Superimposed currents are shown for control trace, suramin block (100 /aM), 
and after 5 min of wash-out. The panel shows the relative maximal currents obtained in the presence of increasing concentrations of suramin. 
The continuous line is the fit to the data as described in Section 2 (IC50 = 13 + 7, N= 3). (B) PPADS inhibition of ATP-evoked currents (10 ~tM 
ATP). The antagonist was preincubated for up to 1 min and co-applied afterwards with the agonist. Superimposed currents are shown for con- 
trol trace, PPADS block (100 p.M) and after 5 min wash-out. The panel represents he relative maximal current obtained in the presence of in- 
creasing concentrations of PPADS. The continuous line is the fit to the data as described in Section 2 (IC50 = 7 +4, N= 3). 
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dium bromide) consistently showed much greater mRNA ex- 
pression in heart than in the other tissues (Fig. 2B). The ex- 
pression of the P2X5 receptor in the cardiovascular system 
seems to be limited to the heart, with no detectable mRNA 
levels in blood vessel cDNA (aorta and vena cava). The P2X4 
receptor is the only one that has been shown previously to 
occur in rat heart [12,13] and therefore a major question will 
be to assess whether both P2X4 and P2X5 isoforms co-assem- 
ble into heteromultimeric receptors. 
3.3. Expression of recombinant P2X5 receptors in HEK293 
cells 
Transient ransfection of HEK-293 cells with a P2X5 full- 
length cDNA resulted in the formation of functional homo- 
meric ATP-gated channels. Fast application of ATP (100 ~tM) 
to cells at -70  mV holding potential induce a rapid inward 
current (,-~ 200-400 pA), which exhibited no voltage rectifica- 
tion and reverted at , - - -5  mV. The channel showed little 
desensitization i  the continuous presence of the agonist 
(Fig. 3A,B). The apparent concentration for half-maximal re- 
sponse (ECs0) to ATP was 8 + 2 [tM. The P2X5 receptor was 
also fully activated by 2MeSATP (EC~0 = 15 +4 ~tM) (Fig. 
3C). The rank order of potency (determined as the magnitude 
of current elicited at 500 p.M) for ATP and other analogs was: 
ATP-->2MeSATP > AMP ~ ADP > dATP = ]],y-meATP. No 
significant current was recorded after application (500 p.M) 
of a,13-meATP, CTP, GTP, UTP or adenosine (Table 1). 
The P2X5 ATP-elicited currents (10 ~tM) were readily 
blocked in a fully reversible manner (< 3 min for complete 
recovery) when co-applied with suramin (ECs0--13 + 7 ~tM) 
(Fig. 4A), but the inhibition observed for PPADS 
(EC~0 = 7 + 4 ~tM) displayed only a partial reversibility (Fig. 
4B). In this respect, it is noteworthy that the P2X5 receptor 
has a lysine residue (K251) which has been shown to be cru- 
cial for the affinity and slow wash-out kinetics of PPADS 
inhibition for the P2X1 and P2X2 receptors [10]. 
The P2X5 isoform displays particular pharmacological nd 
kinetic features which provide the basis for its classification 
with respect o the other P2X receptors. On the basis of the 
lack of effect of a,13-meATP, the P2X5 receptor can be 
grouped together with the P2X2 and P2X4 isoforms [6,9- 
13,17]. The P2X4 channel remains the only receptor cloned 
so far that is insensitive to suramin and PPADS [9,10,12,13], 
while the P2X5 isoform shares, mutually with the P2X1 and 
P2X2 channels, a similar slow rate for the onset and washout 
of PPADS block [17]. 
Taking all these pharmacological data into account, the 
P2X5 receptor exhibits a remarkable similarity to the P2X2 
channel. This resemblance is extended even to the rate of 
desensitization: only the P2X2 and P2X5 receptors experience 
a very low run down of the current in the continuous presence 
of the agonist [6,17]. However, the fact that P2X2 mRNA was 
not detected in rat heart [6], an organ in which P2X5 tran- 
scripts are predominantly expressed, suggests that both pro- 
teins do not fulfil the same physiological functions in native 
systems. 
127 
In conclusion, we have cloned a rat cDNA, that encodes a
novel ATP-gated ion channel, P2X5. This receptor is not ac- 
tivated by cql3-meATP and is blocked by the P2X antagonists 
suramin and PPADS. P2X5 mRNA was found primarily in 
rat heart but is also located in the central nervous system 
(brain and spinal cord) as well as in the adrenal gland. 
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Note added in proof 
When this paper was under revision, a sequence virtually identical 
to the one presented here was published, Collo et al., (1996) J. Neu- 
rosci. 16, 2495~507. A comparison of the protein sequences reveals 
two differences: F191 and Q396 are S191 and R396 in the protein 
described by Collo et al. 
